Renal excretion in experimental hypertensive rats implanted with encapsulated human atrial natriuretic peptide (hANP)-producing cells is circadian periodic. Chinese hamster ovary (CHO) cells transfected with the plasmid hANP-cDNA were encapsulated in biocompatible polycaprolactone capsules for intraperitoneal implantation into two-kidney, one-clip (2K1C) hypertensive rats. During a 12:12 light-dark cycle, as compared to control CHO cells, the implantation of encapsulated hANPproducing CHO cells was associated with an increase in the net excretion of water, sodium and potassium, and with a reversal of the advanced circadian phases related to renovascular hypertension in 2K1C rats. The increase in blood pressure postimplantation was delayed, and increases in renal blood flow, glomerular filtration rate, sodium output, urinary excretion and urinary cyclic GMP concentrations were also found. Implantation of encapsulated hANP-producing cells affects circadian rhythms in kidney excretion functions of 2K1C rats, and may be useful for the treatment of cardiovascular disease.
Introduction
ANP gene delivery in hypertensive animals provides new insights into the role of ANP in hypertension as well as in cardiovascular and renal functions. Circadian variations characterizing the effects of drugs have been reported in the laboratory and in the clinic for over 100 drugs. 1 Circadian rhythms are ubiquitous and relate to many different aspects of pharmacology, such as white cell counts, blood pressure (BP) and renal excretion. Investigations focused mainly on physiological changes after subcutaneous, intramuscular, intravenous and/or oral administration of drugs. 2 Renal sodium handling has been found to be abnormal in patients with hypertension. One example is the exaggerated natriuresis in essential hypertension after volume loading. The circadian stage of maximal urinary sodium excretion has been reported to be different in patients with essential hypertension by comparison with normotensive subjects, for whom maximal urinary sodium excretion reportedly occurs later than maximal potassium excretion. 3 Human atrial natriuretic peptide (hANP), a 28-aminoacid peptide hormone secreted predominantly by atrial cardiomyocytes, has diuretic, natriuretic, vasodilatory, aldosterone-inhibitory, and arterial BP-reducing effects. 4, 5 Numerous physiological responses to exogenous ANP include a rapid natriuresis, diuresis and reduction in arterial BP in hypertensive laboratory animals and humans. 6 These findings suggest that ANP exerts a broad spectrum of beneficial effects for the treatment of hypertension, renal impairment and heart failure. But ANP as such is a poor compound in view of its susceptibility to enzymatic attack in the gut and the circulation, its short half-life, and the need to administer it intravenously. 7 Hypertension has been successfully reversed in adult rats by overexpressing the hANP gene. 8, 9 Difficulties to be overcome in using gene delivery for treating diseases include low gene-transfer efficiency in target tissue, and means to improve immunological tolerance, safety and transgene expression. 10 If naked plasmid DNA is in contact with cell membranes, only a small amount will pass into the cell, leading to a low gene-transfer efficiency. Therefore, carrier molecules or virus vectors are often used to increase the gene-transfer efficiency. Although many may give useful results, none is optimal for clinical studies; side effects have been found in clinical trials. 10, 11 Another approach of gene therapy developed to overcome these obstacles consists of implanting microencapsulated gene-transfection cells. [12] [13] [14] [15] The engineered cells are encapsulated to prevent them from having contact with host tissues. We used a technique based on local delivery of hANP from genetically engineered Chinese hamster ovary (CHO) cells, using capsules that can be implanted in the body for therapeutic protein or peptide release in the treatment of cardiovascular diseases.
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Results
Group data are expressed as means7s.e.m.
Engineering encapsulated cells secreting hANP
hANP secreted by hANP-producing cells in medium was analyzed by a radioimmunoassay (RIA) specific for hANP. hANP secreted by hANP-producing cells encapsulated in biocompatible polycaprolactone (PCL) capsules was detected 3 days after encapsulation at a concentration of 46.5 pg/ml/24 h in 2 ml medium and reached an average concentration of 246.1 pg/ml/24 h in 2 ml medium from day 8 after encapsulation. hANP secreted by encapsulated hANP-producing cells could be detected in medium for at least 6 months. No hANP cDNA-transfected CHO cells were found under microscopic examination at any time in medium outside the PCL capsules.
Blood pressure reduction after implantation of encapsulated hANP-producing cells
The systolic BP of rats 2 weeks after renal artery constriction was statistically significantly higher than that of sham-operated rats (14373 versus 12174 mmHg, n ¼ 20, Po0.001). The BP of rats was measured every day for 6 weeks after implantation of PCL capsules. Implantation of encapsulated hANP-producing cells into the peritoneal cavity of two-kidney, one-clip (2K1C) hypertensive rats blunted the increase in systolic BP seen in rats of the CHO-group, Figure 1 . It can be seen that implantation of encapsulated engineered cells harboring the hANP gene was associated with a delay in BP increase 2 days after implantation, the effect lasting for more than 5 months. On the average, the BP reduction was maximal 42 days after implantation, amounting to 28 mmHg (hANP-CHO-versus CHO-rats: 159710 versus 18777 mmHg, n ¼ 20, Po0.05), Figure 1 . The difference in systolic BP between hANP-CHO-rats (165712 mmHg, n ¼ 10) and CHO-rats (19778 mmHg, n ¼ 10) remained significant (Po0.05) 5 months after implantation.
Effects of capsule implantation on physiological variables
As shown in Table 1 , 30 days after implantation of encapsulated hANP-producing cells, as compared to rats in the CHO-group, rats in the CHO-hANP group had an increased urine excretion (17.472.1 versus 10.271.7 ml/ 100 g BW/day, n ¼ 10, Po0.05), whereas water intake did not differ significantly (13.572.3 versus 8.571.6 ml/100 g BW/day, n ¼ 10, P40.05). Urine sodium output (USO) was increased by a factor of 6.5 (0.5970.08 versus 0.0970.01 mmol/100 g BW/day, n ¼ 10, Po0.001), and urinary cyclic GMP (cGMP) concentrations were increased by a factor of 4.5 (35.5279.28 versus 7.9171.08 nmol/100 g BW/day, n ¼ 10, Po0.01), but there was no statistically significant difference in urinary total protein excretion between the two groups.
Effects of capsule implantation on renal function
At 45 days after implantation with encapsulated hANPproducing CHO cells, the glomerular filtration rate (GFR) of 2K1C rats in the CHO-hANP group was increased by a factor of 3.6 as compared to rats in the CHO-group (0.7970.02 versus 0.2270.07 ml/min/g kidney weight, n ¼ 10, Po0.001), Table 2 . Renal blood flow (RBF) was also increased by a factor of 2.4 (7.3570.19 versus 3.0971.28 ml/min/g kidney weight, n ¼ 10, Po0.01), and the hematocrit was decreased by 40% (4877 versus 6274, n ¼ 10, Po0.05), Table 2 . There was no statistically significant difference in renal function measurements between rats in the CHO-hANP group and those in the sham-operated group, Table 2 .
Effects of capsule implantation on plasma ANP concentrations
The expression concentrations of plasma hANP in all experimental rats were assayed by a RIA specific for hANP. The concentrations of immunoreactive hANP were detectable in rats of the CHO-hANP group (217.3711.3 pg/ml plasma, n ¼ 10) at 10 days postim- 
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Immunoreactive hANP could be detected in rats of the CHO-group (82.5710.5 pg/ml plasma, n ¼ 10. These results indicate that goat anti-hANP antibody has some cross-reactivity with rat ANP by RIA. Human and rat ANP are not immunologically identical, however, and are distinguishable by RIA (Po0.001).
Circadian rhythmicity of renal excretion Diuresis (data given in the table below). Circadian rhythms with different characteristics are found for urinary water excretion in rats of the three groups Natriuresis (data given in the table below). As was the case for urinary water excretion, circadian rhythms with different characteristics are found for urinary sodium excretion in rats of the three groups (Po0.005), Figure 2b . By comparison with the CHO-group, implantation of encapsulated hANP-producing cells (CHO-hANP group) was associated with an increase in urinary sodium excretion (from 0.036 to 0.066 mmol/100 g BW/ 4 h, F ¼ 209.0, Po0.001), with an increased circadian amplitude (from 0.013 to 0.017, F ¼ 44.91, Po0.001), and with an acrophase advance of about 3.6 h (from 04:44 to 01:08, F ¼ 556.5, Po0.001), Figure 2b . Peak urinary sodium excretion occurs during the nocturnal active span of the 2K1C rats in both groups. As for the case of diuresis, implantation of encapsulated hANP-producing cells partly restored the circadian pattern of urinary sodium excretion seen in sham-operated rats, notwithstanding remaining differences in acrophase (01:08 versus Kaliuresis (data given in the table below). As was the case for urinary water and sodium excretion, circadian rhythms with different characteristics are found for urinary potassium excretion in rats of the three groups (Po0.001), Figure 2c . Implantation of encapsulated hANP-producing cells was associated with an increase in urinary potassium excretion (from 0.036 to 0.069 mmol/100 g BW/4 h, F ¼ 274.2, Po0.001), with an 
Discussion
Renal excretion displays a circadian rhythm that is synchronized with the light-dark cycle, resulting in highest renal excretion during the night when rats are active and in lowest renal excretion during the daytime when rats typically sleep. 16 Placing a constricting silver clip around the left renal artery not only resulted in severe hypertension, but also greatly altered the usual circadian pattern of renal excretion, including a 3.5-4.8 h advance in acrophase, Figure 2 . These results are in keeping with the proposition that encapsulated hANPproducing cells can restore, at least in part, the circadian rhythm of renal excretion, disrupted by renovascular hypertension. This finding of an effect of hANP on kidney function shows promise for a treatment based on the implantation of hANP-cDNA transfected CHO cells encapsulated in PCL capsules, notably since the 24 h mean values of renal variables did not differ between rats in the CHO-hANP and sham-operated groups, Table  2 . Sham-operated Wistar rats displayed marked circadian variations in water, sodium and potassium excretion, peaking during the nocturnal active stage of the rats. These findings are in agreement with previous reports documenting the prominence of circadian rhythms related to kidney function in healthy subjects. 17 The present in vivo study shows that a continuous supply of hANP by implantation of hANP-cDNA transfected CHO cells encapsulated in PCL capsules into bodies of 2K1C hypertensive rats was associated with a sustained delay in the increase of BP as well as with an attenuation of renal injury. The ability of implantation of encapsulated hANP-cDNA transfected CHO cells to protect against structural changes in the heart and kidney of 2K1C rats is a step forward toward a therapeutic approach of hANP gene expression in renal hypertension or cardiovascular disorders. In our study, exogenous hANP expression in 2K1C rats resulted in a statistically significant and prolonged reduction in BP postimplantation of encapsulated hANP-producing cells. This hypotension is likely accounted for by the binding of hANP expressed by exogenous gene to ANP receptors, followed by the triggering of a cGMP-coupled signal transduction pathway, and subsequent vascular relaxation and lowered BP. 18 This notion is supported by the finding that an increase in cGMP concentrations was detected in rat urine after the implantation of encapsulated plasmid hANP-cDNA-transfected CHO cells.
The effect of ANP infusion on renal function in animals or humans has been the subject of extensive study. 16 ANP infusion (80-300 ng/min/kg) was associated with a statistically significant increase in urine flow, USO, GFR and RBF. 16 Herein, encapsulated hANPproducing cells effectively improved renal dysfunction associated with experimental hypertension in 2K1C rats via an increase in GFR and RBF. Implantation of encapsulated hANP-producing cells, however, reportedly attenuated renal artery clip-induced glomerular, tubular, and arterial lesions consistent with decreases in GFR and RBF. 19, 20 Implantation of encapsulated hANP-producing cells can compensate for renal dysfunction in 2K1C rats by maintaining the coordination of total-body fluid and electrolytes. The feasibility of somatic ANP gene therapy was demonstrated for the treatment of hypertension in a different animal model. 8, 21 Besides the intravenous delivery of plasmid RSV-cANP DNA, intravenous delivery of viral vectors encoding the ANP gene were also reported. 8, 21, 22 The efficiency and uptake of naked ANP plasmid DNA by direct intravenous injection, however, may be quite low and the somatic delivery of RSV-cANP construct in human gene therapy could only prolong the expression duration by a few weeks. 8, 21, 23 This is not satisfactory for the long-term treatment of hypertension. Studies by Chao et al also showed that adenovirus-mediated gene delivery achieved a level of expression within 3 days, and the effect lasted for more than 5 weeks. 8 Adenovirus-mediated gene delivery of hANP led to a prolonged BP reduction and resulted in partially protective effects in high salt diet-induced cardiac hypertrophy and severe renal damage in Dahl salt-sensitive rats. However, immunosurveillance by the host may attenuate or stop the therapeutic efficacy of adenovirus-mediated gene delivery. Therefore, adeno-associated virus-mediated gene infusion was not compatible with long-term and high-efficiency gene expression. 22, 23 Moreover, ensuring the safety of gene transfer agents for therapeutic intervention is an important step toward the development of clinically successful gene therapies. Of more than 400 clinical protocols for human gene therapy, only few have been successful and many obstacles remain. One major hurdle is safety, and safety of gene therapy is of paramount importance. 22, 24 The occurrence of lymphoma in monkeys after injection with a retroviral vector, and the death of a patient with an inherited enzyme deficiency after injection with an adenoviral vector point to the need for safety evaluations of gene therapy vectors in nonhuman primate models prior to the initiation of clinical trials. 24 Implantation of encapsulated hANP-producing cells in PCL capsules permeable to hANP, but impermeable to the cells is of potential interest in the long-term treatment of hypertension and other diseases. PCL capsules protect vector cells from rejection and make it possible to end the treatment, if needed, by removing the PCL capsules. They prevent cell trafficking or uncontrolled cell line proliferation in recipient animals.
PCL have been widely used as carriers of cells in view of their biocompatibility. They could thus be used as cell carriers in the human body for long spans. [25] [26] [27] [28] Our study confirmed the potential use of PCL capsules as plasmid hANP-cDNA-transfected cell carriers, able to be implanted in the body for the long-term release of hANP. Several features of this device can help improve the feasibility of in vivo gene therapy. 15 First, the capsules segregate the grafted cells from the host's tissues. If need Circadian renal excretion rhythms modified by hANP LG Chen et al be, all the cells can be removed by a simple surgical procedure. Second, the capsules protect engineered cells from rejection, allowing the use of immortalized allogeneic cells from a single donor to be implanted into a number of hosts. Results herein suggest the potential use of implanted encapsulated hANP-producing cells to compensate for an impaired renal and cardiovascular function in patients with renal artery hypertension. This study thus has potentially important implications for the treatment of cardiovascular and other diseases where long-term delivery of secreted transgenes is a desirable therapeutic option.
Materials and methods
Animal model
Goldblatt hypertension was induced in 5-week-old male Wistar rats (Medical Animal Center of Sichuan University). The rats were prepared by placing a constricting silver clip (internal gap 0.2 mm) around the left renal artery under anesthesia with pentobarbital sodium (50 mg/kg BW i.p.). For sham-operated rats, an incision was made in the left flank to expose the kidney and the renal artery without clipping the vessel. 19 Procedures and protocols were in accordance with institutional guidelines 8 and were approved by the institutional review board of Sichuan University (Chengdu, PR China). The light phase was from 0700 to 1900 with 500 lx artificial light. The dark phase extended from 1900 to 0700. During the entire experiment, including the time when the rats were housed in metabolic cages, they were fed the same diet and distilled water.
Preparation of encapsulated hANP-producing cells
Polycaprolactone (PCL) capsules (obtained from Tianjin Biomaterial Company, PR China) consist of 85% PCL and 15% pluronics. Mean molecular weight (MW) of PCL is 50 000 Da and the MW range of pore permeability of the PCL is from 2000 to 10 000 Da (ANP MW about 3000 Da). 7 PCL capsules used for implantation are 30 mm in length and 3 mm in diameter. Before the cells were encapsulated in PCL capsules, the PCL capsules had been decontaminated with Co-60g for 60 min. Plasmid RSV-cANP was constructed as previously described. 21 CHO cells (Cell Bank of Chinese Academy of Sciences, PR China) were transfected with the plasmid RSV-cANP by Lipofectamine (lot: KHVY01, Lifetechnologies). The CHO cells were then allowed to undergo selection in G 418 (lot: 1103616, GIBCO/BRL Co) (600 mg/ ml) for about 6-10 days, and G 418 -resistant colonies were isolated and expanded in culture medium. The transfected cells were suspended in medium at a concentration of 3 Â 10 6 cells/ml and the suspension (300 ml) was set in PCL capsules using a syringe.
Capsule implantation
At 2 weeks after renal artery clipping, the 2K1C hypertensive rats were randomly subdivided into two groups. 19 The 2K1C hypertensive rats in the CHO-hANP group were implanted with encapsulated hANP-producing CHO cells (one PCL capsule) into the peritoneal cavity. The 2K1C hypertensive rats in the CHO-group were implanted with PCL capsules containing CHO cells transfected with control vector DNA. Before implantation, PCL capsules were removed from the culture medium, washed 15 times with 5 volumes of PBS at 371C and kept on ice until needed. Implantation surgeries were carried out under general anesthesia. After surgical preparation of the abdomen, a 3-cm midline incision was made from caudal to the umbilicus through the linea alba. The PCL capsules were implanted into the peritoneal cavity and fixed on the peritoneal wall. The peritoneal walls were closed using sutures, and the skin incisions were closed using skin staple. Analgesics were administered and the rats were removed to recovery.
Urine collection and analysis of physiological variables
Urine samples (24 h) were collected from the rats in metabolic cages 30 days after the implantation of PCL capsules for determination of cGMP, USO, and total protein. 29 To avoid contamination of urine samples, the rats received only water during the 24 h collection span.
29,30
Measurement of blood pressure and renal function
The systolic BP of rats was measured with a manometertachometer (KN-210; Nastume Seisakusho, Tokyo, Japan) using the tail-cuff method. 8 Unanesthetized rats were introduced into a plastic holder mounted on a thermostatically controlled warm plate, which was maintained at 33-351C during measurement. An average of 10 readings was taken for each rat after they became acclimated to the environment. Renal function was measured at 45 days after implantation of PCL capsules. The GFR was determined from the clearance of polyfructosan. The RBF was determined from the clearance of p-aminohippuric acid and the hematocrit. Clearance data were normalized to kidney weight. 8, 29, 30 Concentrations of plasma hANP and urinary cGMP Blood was extracted from rats by direct cardiac puncture at 0800, centrifuged at 1000 g for 5 min, and the plasma was collected. The concentration of hANP in plasma was determined by a RIA specific for hANP.
14 Urinary cGMP was assayed as previously described. 29 
Morphological analysis
Rats from each group were anesthetized intraperitoneally with pentobarbital at a dose of 30 mg/kg body weight (BW) 45 days after implantation of PCL capsules. The rats were perfused with normal saline (0.9% NaCl) by cardiac puncture, and the whole heart, left ventricle, both kidneys and aorta were removed, blotted, and weighed.
Circadian rhythmicity of renal excretion
Circadian rhythmicity of renal excretion 3,31-35 was studied 35 days postimplantation of PCL capsules. Urine samples were collected every 4 h (0700-1100, 1100-1500, 1500-1900, 1900-2300, 2300-0300, 0300-0700) from the rats kept in metabolic cages for 24 h. Urinary volume was determined for each sample (ml/100 g BW/4 h). Urinary excretion rates of sodium and potassium (mmol/100 g BW/4 h) were determined using an E2A Beckman spectrophotometric analyzer. All experiments were performed in a controlled sound-dampened room, under constant conditions of temperature (25711C) and humidity (6575%) with lights on (artificial light of Circadian renal excretion rhythms modified by hANP
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